CollPlant Biotechnologies (CLGN) Change in Account Payables (2020 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Change in Account Payables came in at -$8000.0 in Q4 2025, up 94.24% YoY from -$4118.5 in Q4 2024, and down 117.02% on a QoQ basis from $47000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Change in Account Payables (2020 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 6 years of Change in Account Payables data on file, last reported at -$8000.0 in Q4 2025.
- Quarterly Change in Account Payables rose 94.24% year-over-year to -$8000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$299000.0 (down 171.82% YoY) and the FY2025 annual result came in at -$260000.0, down 136.36% from the prior year.
- Change in Account Payables eased to -$8000.0 in Q4 2025, from $47000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $253000.0 in Q4 2022 to a low of -$248000.0 in Q1 2023.
- A 5-year average of -$4631.6 and a median of -$8000.0 in 2025 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 695.24% in 2021, down 1881.82% in 2021.
- Tracing CLGN's Change in Account Payables over 5 years: stood at $169000.0 in 2021, then jumped by 49.7% to $253000.0 in 2022, then slipped by 6.72% to $236000.0 in 2023, then plunged by 158.9% to -$139000.0 in 2024, then jumped by 94.24% to -$8000.0 in 2025.
- The last three Change in Account Payables figures came in at -$8000.0 (Q4 2025), $47000.0 (Q3 2025), and -$199000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Jun 30, 2025 | -199,000.00 |
| Jun 30, 2025 | -199,000.00 |
| Dec 31, 2024 | -139,000.00 |
| Dec 31, 2024 | -139,000.00 |
| Sep 30, 2024 | -129,000.00 |
| Sep 30, 2024 | -129,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 139,000.00 |
| Mar 31, 2024 | 139,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Sep 30, 2023 | -19,000.00 |
| Sep 30, 2023 | -19,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -122,000.00 |